Form 4 for KURA Kura Oncology, Inc.
Accepted 2026-08-17 16:45:03 ET · period of report 2026-08-17 · accession 0001193125-26-354201 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2026-08-17 16:45 | 2026-08-17 | KURA | WILSON TROY EDWARD | Pres, CEO, Dir | P - Purchase | $11.12 | +100.0K | 379.2K | +36% | +$1.11M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-17 | P | A | 100,000 | $11.12 | 379,194 | I by One Fish Two Fish Revocable Trust | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $10.87 to $11.31. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |